論文・技術情報追加のお知らせ

1. A Real-World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database.

ベリムマブは副作用が多様で、特に女性患者に注意が必要

対象DB：FAERS

2. Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the united states food and drug administration adverse event reporting system.

PARP阻害薬による副作用は薬剤や国によって異なる

対象DB：FAERS

3. Drug-induced liver injury associated with pretomanid, bedaquiline, and linezolid: Insights from FAERS database analysis.

BPaL治療はDILIリスクがあり、注意が必要

対象DB：FAERS

4. Keratoconus Cases Associated with Medication Use: A Population-Based Pharmacovigilance Study.

ケラトコナスは特定の薬剤と関連があり、注意が必要

対象DB：FAERS

5. Adverse reaction of specific acute kidney injury caused by atorvastatin: an actual study based on the database of the US FDA adverse event reporting system.

アトルバスタチンは一般的に安全だが、特定の集団で急性腎障害に注意が必要

対象DB：FAERS

6. A real-world adverse events study of rimegepant from the FAERS database.

リメゲパンの副作用に新たな懸念

対象DB：FAERS

7. Diabetic adverse events associated with three commonly used statins: a disproportionality analysis based on the FDA adverse event reporting system database.

スタチン使用は糖尿病リスクを高め、特に女性で顕著

対象DB：FAERS

8. Thromboembolism adverse event profiles of thrombopoietin receptor agonists: a real-world, pharmacovigilance study.

TPO-RAsは血栓症リスクを高め、特に静脈血栓症が多い

対象DB：FAERS

9. Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System.

CAR-T療法に関連する神経毒性は頻繁で、製品ごとに異なる特徴を示す

対象DB：FAERS

10. Relationship of urate-lowering drugs with cognition and dementia: A Mendelian randomization and observational study.

尿酸降下薬は認知機能や認知症との関連がない可能性

対象DB：FAERS

11. Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system.

DPP-4阻害薬は胆嚢疾患と関連性あり、GLP-1受容体作動薬は弱い関連を示す

対象DB：FAERS

12. Disproportionality analysis of drug-induced dry mouth using data from the United States food and drug administration adverse event reporting system database.

薬剤性口渇の原因薬を特定。ティオトロピウムが最も多く、認識と管理の重要性を強調

対象DB：FAERS

13. Safety study on adverse events of zanubrutinib based on WHO-VigiAccess and FAERS databases.

ザヌブルチニブの副作用を確認し、新たなリスクを特定

対象DB：FAERS

14. Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database.

薬剤による心筋炎のリスクが示され、特にクロザピンと免疫療法薬に注意が必要

対象DB：FAERS

15. Interstitial lung disease associated with ALK inhibitors and risk factors: an updated comparative pharmacovigilance analysis.

ALK阻害剤は肺毒性のリスクがあり、特に併用薬に注意が必要

対象DB：FAERS

16. Investigation of spontaneous abortion and stillbirth adverse events in epilepsy patients treated with levetiracetam: A pharmacovigilance study.

レベチラセタムは流産や死産のリスクと関連し、特に妊娠中の使用で注意が必要

対象DB：FAERS

17. Clinical adverse events to letairis: a real-world drug safety study based on FDA Adverse Event Reporting System (FAERS).

Letairisは重大な副作用を引き起こす可能性があり、特に女性と高齢者で注意が必要

対象DB：FAERS

18. Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors used in Patients with Diabetes Mellitus and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database.

SGLT2iの副作用は糖尿病患者と心不全患者で異なり、適切な管理が重要

対象DB：JADER

19. Risks Associated with the Use of Intranasal Corticosteroids: An Analysis of Adverse Reactions Reported to EudraVigilance.

INCSの副作用は女性に多く、特に「嗅覚喪失」と「味覚喪失」が注目された

対象DB：EudraVigilance

20. Association between exposure to proton pump inhibitors and delirium: a descriptive and disproportionality analysis of VigiBase.

PPI使用とせん妄の関連は明確でないが、低ナトリウム血症との関連が示唆されている

対象DB：VigiBase

21. Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness.

トラスツズマブのバイオシミラーは安全性に差がなく、コスト削減につながる

対象DB：MDV,VigiBase

22. Suicidal behaviour and CFTR modulators: A case series and WHO database disproportionality analysis.

CF治療薬ETIは自殺行動の報告増加に関連し、用量依存の影響が示唆される

対象DB：VigiBase

23. Rheumatic Adverse Effects With Biologics Targeting Type 2 Inflammation In Severe Asthma: A Vigibase(R) Study.

重度喘息の生物学的製剤は、VigiBaseでリウマチ疾患や症状の報告が増加しており、製剤ごとに副作用のプロファイルが異なる

対象DB：VigiBase

24. Disproportionality analysis of flutamide- or bicalutamide-induced liver injury with and without steroids by using the Japanese Adverse Drug Event Report database.

フルタミドやビカルタミドは肝障害リスクを増加させ、ステロイド使用がその管理に有効である可能性

対象DB：JADER

25. Early effect of a financial incentive for surgeries within 48 h after hip fracture on the number of expedited hip fracture surgeries, in-hospital mortality, perioperative morbidity, length of stay and inpatient medical expenses.

2022年の財政的インセンティブ導入後、股関節骨折手術に有意な短期効果は見られなかった

対象DB：DPC

26. Factors Affecting Treatment Persistence in Japanese Patients with Psoriasis Prescribed Biologics: A Real-World Study Using an Insurance Claim Database.

生物学的製剤では、インフリキシマブが最も長く持続し、グセクマブが1年生存率最高

対象DB：JMDC

27. Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in England.

多発性硬化症患者は高血圧管理目標を達成しやすいが、循環器合併症は増加

対象DB：CPRD

28. Dependent censoring bias assessment using inverse probability of censoring weights: Type 2 diabetes mellitus risk in patients initiating bisoprolol versus other antihypertensives in a Clinical Practice Research Datalink cohort study.

ビソプロロールとACEi/ARBでT2DMリスクに有意差なし

対象DB：CPRD

29. Time Series Methods to Assess the Impact of Regulatory Action: A Study of UK Primary Care and Hospital Data on the Use of Fluoroquinolones.

2019年RMM導入後、フルオロキノロン使用が大幅に減少

対象DB：CPRD

30. Prioritising primary care patients with unexpected weight loss for cancer investigation: diagnostic accuracy study (update).

50歳以上の男性や60歳以上の女性で予期せぬ体重減少はがんリスクが高い

対象DB：CPRD

31. Opportunities and challenges for identifying undiagnosed Rare Disease patients through analysis of primary care records: long QT syndrome as a test case.

LQTSの早期診断にEHRデータから予測モデルを開発可能

対象DB：CPRD

32. Heart failure and major haemorrhage in people with atrial fibrillation.

心不全合併のAF患者は出血リスクが高く、予測が過小評価される傾向

対象DB：CPRD

33. Treatment for osteoporosis and risk of osteonecrosis of the jaw among female patients in the United Kingdom Clinical Practice Research Datalink.

骨吸収抑制薬使用後、ONJリスクは低いが治療2-3年後に増加

対象DB：CPRD

34. Effect of a Financial Incentive Scheme for Medication Review on Polypharmacy in Elderly Inpatients With Dementia: A Retrospective Before-and-After Study.

2016年の薬剤削減インセンティブ導入後も、認知症高齢患者の退院時の薬剤数に変化なし

対象DB：DeSC